BTIG Research Reaffirms “Buy” Rating for MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. BTIG Research’s target price points to a potential upside of 105.88% from the stock’s current price.

A number of other equities research analysts have also commented on MDXH. TD Cowen upped their price target on MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded MDxHealth to a “hold” rating in a report on Saturday, August 30th. Lake Street Capital raised their price target on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

MDxHealth Trading Up 7.9%

MDXH opened at $3.40 on Tuesday. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.14 and a quick ratio of 1.02. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $5.33. The company’s 50 day moving average price is $3.89 and its two-hundred day moving average price is $3.34. The firm has a market capitalization of $160.79 million, a price-to-earnings ratio of -5.31 and a beta of 1.59.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. As a group, research analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

Institutional Trading of MDxHealth

Hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP bought a new position in MDxHealth during the third quarter worth $48,000. Lido Advisors LLC acquired a new position in shares of MDxHealth during the third quarter valued at about $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth about $53,000. Hudson Bay Capital Management LP acquired a new stake in shares of MDxHealth in the 3rd quarter valued at about $70,000. Finally, Bank of America Corp DE grew its stake in shares of MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after buying an additional 14,769 shares during the period.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.